Trials / Completed
CompletedNCT05492201
A Study of LY3873862 in Healthy Participants
A Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3873862 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3873862 when administered either in single or multiple doses in healthy participants. The study will also assess how fast LY3873862 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 58, 72, and 72 days for Part A, B, and C, respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3873862 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2022-08-11
- Primary completion
- 2025-04-29
- Completion
- 2025-04-29
- First posted
- 2022-08-08
- Last updated
- 2025-05-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05492201. Inclusion in this directory is not an endorsement.